Sign In
Buy EIGR
$1.73
+0 (+0%)
At Close: Aug 27, 2024
PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of first-in-class therapies for serious rare and ultra-
Stocks To Watch: Spotlight On Palo Alto Networks, Best Buy And Xpeng Motors
08:12am, Saturday, 22'nd Aug 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Eiger BioPharmaceuticals (EIGR) Catches Eye: Stock Jumps 8.6%
12:49pm, Wednesday, 19'th Aug 2020
Eiger BioPharmaceuticals (EIGR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Insider Buying: The Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Founder Just Bought 4.7% More Shares
11:40am, Monday, 17'th Aug 2020
Potential Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) shareholders may wish to note that the Founder, Jeffrey Glenn...
Stocks To Watch: Walmart, Target, Kandi And Gold vs. Bitcoin
08:30am, Saturday, 15'th Aug 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Eiger BioPharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
08:05pm, Thursday, 06'th Aug 2020
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for sec
Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor Conferences
12:00pm, Monday, 03'rd Aug 2020
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will part
BidaskClub Lowers Eiger Biopharmaceuticals (NASDAQ:EIGR) to Strong Sell
06:25am, Monday, 27'th Jul 2020
BidaskClub cut shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) from a sell rating to a strong sell rating in a research report released on Friday morning, BidAskClub reports. Other research analysts
I have been discussing the idea that the tragic coronavirus pandemic presents a unique opportunity in which a healthcare event can lead to profitable investments.
Is Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Popular Amongst Institutions?
04:16pm, Friday, 17'th Jul 2020
Every investor in Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) should be aware of the most powerful shareholder...
Antivirals In The COVID-19 Space
06:33pm, Monday, 13'th Jul 2020
A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.
Did Hedge Funds Make The Right Call On Eiger BioPharmaceuticals, Inc. (EIGR) ?
12:14am, Monday, 13'th Jul 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile market
Eiger BioPharma (EIGR) Upgraded to Strong Buy: What Does It Mean for the Stock?
04:00pm, Wednesday, 08'th Jul 2020
Eiger BioPharma (EIGR) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) Shares Purchased by Deutsche Bank AG
05:18am, Monday, 06'th Jul 2020
Deutsche Bank AG increased its stake in shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) by 306.4% in the 1st quarter, HoldingsChannel reports. The firm owned 52,683 shares of the biotechnology co
Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) Stake Raised by Nuveen Asset Management LLC
04:22am, Sunday, 05'th Jul 2020
Nuveen Asset Management LLC boosted its holdings in Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) by 196.9% during the 1st quarter, according to the company in its most recent disclosure with the Securit
